Clinical Trial Update: A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) [Phase 3]

View source ↗

Summary

This is a status update for a Phase 3 confirmatory trial in non-small cell lung cancer patients with MET exon 14 mutation, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Beijing Pearl Biotechnology Limited Liability Company | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING